GBI
Research, the leading business intelligence provider, has released its latest
research: Obesity Therapeutics to 2019 – Safety Concerns Hinder Drug
Performance Despite Large Market Opportunity”. Obesity is often described as a
global endemic, with incidence dramatically increasing over the past decades,
particularly in developed countries. Being overweight or obese is a major risk
factor in the development of many chronic diseases, including cardiovascular
diseases, cancer, and diabetes, of which treatment incurs extensive economic
and healthcare costs.
To Read the Complete Report with TOC
Visit:
http://www.marketresearchreports.biz/analysis-details/obesity-therapeutics-to-2019-safety-concerns-hinder-drug-performance-despite-large-market-opportunity
Numerous
anti-obesity drugs have been approved in the past decade, including Knoll
Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them
to be removed from the market due to evidence of suicidal thoughts, depression
and cardiovascular problems with their long-term use. As such, healthcare
professionals have a negative perception of such drugs and do not widely
prescribe them, a major barrier to the growth of the anti-obesity therapeutics
market. Only orlistat is currently deemed safe for the long-term treatment of
obesity; being proven to produce a placebo-adjusted weight-loss average of a
limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and
GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety
and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose)
profile to make a significant impact on the market, providing it is proven safe
in long-term-use studies.
If
proven safe, GBI Research expects the sales of Qsymia and other drugs expected
to be approved over the forecast period to increase the market size to $2.7
billion. Although moderate, this is significantly below the market potential
given the size of the prevalence population. Optimally safe and effective
anti-obesity drugs which overcome healthcare professionals’ negative opinions
will have to be developed if the size of the market is ever to reflect the
prevalence of obesity.
Scope
The
report analyzes the incidence of obesity, current treatment options, pipeline
and market forecasts, and deals surrounding anti-obesity drugs.
The
report includes:
- A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options
- Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug’s expected performance within the forecast period
- Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action
- Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type
- An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes.
- A detailed discussion of the drivers and barriers for this immature market
To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/173940
Reasons
to Buy
The
report will enhance your decision-making capability by allowing you to:
- Understand the large number of potential molecular targets for the development of an anti-obesity drug, as well as the strengths, weaknesses, and risks of each drug type
- Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development
- Observe the trends in clinical trial duration and size by Phase, molecule type and mechanism of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and future developmental programs
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market
- Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and in depth details of the highest value deals
Contact
M/s
Sheela
90
Sate Street, Suite 700
Albany,
NY 12207
USA
– Canada Toll Free: 866-997-4948
No comments:
Post a Comment